Avid Bioservices Past Earnings Performance
Past criteria checks 0/6
Avid Bioservices has been growing earnings at an average annual rate of 42.7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 22.7% per year.
Key information
42.7%
Earnings growth rate
43.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 22.7% |
| Return on equity | -9.8% |
| Net Margin | -12.9% |
| Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Avid Bioservices makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 137 | -18 | 27 | 0 |
| 31 Oct 23 | 141 | -12 | 27 | 0 |
| 31 Jul 23 | 150 | -3 | 28 | 0 |
| 30 Apr 23 | 149 | 1 | 28 | 0 |
| 31 Jan 23 | 141 | 116 | 26 | 0 |
| 31 Oct 22 | 134 | 119 | 25 | 0 |
| 31 Jul 22 | 126 | 123 | 23 | 0 |
| 30 Apr 22 | 120 | 128 | 21 | 0 |
| 31 Jan 22 | 116 | 10 | 20 | 0 |
| 31 Oct 21 | 106 | 9 | 19 | 0 |
| 31 Jul 21 | 101 | 6 | 18 | 0 |
| 30 Apr 21 | 96 | 3 | 17 | 0 |
| 31 Jan 21 | 81 | 0 | 16 | 0 |
| 31 Oct 20 | 73 | -5 | 15 | 0 |
| 31 Jul 20 | 70 | -7 | 14 | 0 |
| 30 Apr 20 | 60 | -15 | 15 | 0 |
| 31 Jan 20 | 64 | -10 | 15 | 0 |
| 31 Oct 19 | 64 | -9 | 15 | 0 |
| 31 Jul 19 | 56 | -11 | 14 | 0 |
| 30 Apr 19 | 54 | -10 | 13 | 0 |
| 31 Jan 19 | 43 | -16 | 13 | 0 |
| 31 Oct 18 | 37 | -24 | 15 | 0 |
| 31 Jul 18 | 39 | -30 | 16 | 0 |
| 30 Apr 18 | 54 | -25 | 16 | 0 |
| 31 Jan 18 | 65 | -17 | 18 | 0 |
| 31 Oct 17 | 69 | 6 | 17 | -16 |
| 31 Jul 17 | 79 | 11 | 18 | -9 |
| 30 Apr 17 | 58 | -3 | 18 | 0 |
| 31 Jan 17 | 59 | -17 | 18 | 16 |
| 31 Oct 16 | 54 | -48 | 19 | 47 |
| 31 Jul 16 | 41 | -57 | 19 | 54 |
| 30 Apr 16 | 44 | -1 | 18 | 0 |
| 31 Jan 16 | 35 | -60 | 19 | 55 |
| 31 Oct 15 | 34 | -56 | 19 | 51 |
| 31 Jul 15 | 31 | -55 | 19 | 47 |
| 30 Apr 15 | 27 | -54 | 19 | 43 |
| 31 Jan 15 | 24 | -51 | 18 | 40 |
| 31 Oct 14 | 22 | -47 | 18 | 36 |
| 31 Jul 14 | 23 | -42 | 18 | 33 |
| 30 Apr 14 | 22 | -36 | 17 | 28 |
| 31 Jan 14 | 20 | -34 | 17 | 25 |
| 31 Oct 13 | 23 | -29 | 15 | 24 |
| 31 Jul 13 | 22 | -30 | 15 | 23 |
| 30 Apr 13 | 22 | -30 | 13 | 24 |
Quality Earnings: TEHP is currently unprofitable.
Growing Profit Margin: TEHP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TEHP is unprofitable, but has reduced losses over the past 5 years at a rate of 42.7% per year.
Accelerating Growth: Unable to compare TEHP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TEHP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: TEHP has a negative Return on Equity (-9.81%), as it is currently unprofitable.